Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype.

ABSTRACT:

Background

LIV1 is a transmembrane protein that may become a new therapeutic target through the development of antibody-drug conjugates (ADCs). Few studies are available regarding the assessment of LIV1 expression in clinical breast cancer (BC) samples.

Methods

We analyzed LIV1 mRNA expression in 8982 primary BC. We searched for correlations between LIV1 expression and clinicopathological data, including disease-free survival (DFS), overall survival (OS), pathological complete response to chemotherapy (pCR), and potential vulnerability and actionability to anti-cancer drugs used or under development in BC. Analyses were performed in the whole population and each molecular subtype separately.

Results

LIV1 expression was associated with good-prognos

SUBMITTER: de Nonneville A 

PROVIDER: S-EPMC10058875 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature